进展性纤维化间质性肺病的蛋白质组学生物标志物:多中心队列分析
该多中心队列分析在加州大学发现队列385例和德州大学验证队列204例间质性肺病患者中,使用靶向蛋白质组学平台检测368种血浆标志物,以1年内死亡、肺移植或FVC相对下降≥10%定义进展。发现31种标志物与进展相关,17种在验证队列中保持关联;机器学习衍生的12种标志物蛋白质组特征在验证队列中敏感度0·90、阴性预测值0·91。
要点
- 17种血浆生物标志物与进展性纤维化ILD相关,且在各临床亚型中一致。
- 12种标志物蛋白质组特征预测1年进展敏感度0·90、阴性预测值0·91。
- 高风险特征患者FVC变化为-227·1 mL,低风险者为+85·7 mL。
核心结论
- 鉴定出17种进展性纤维化间质性肺病的血浆生物标志物,在不同ILD亚型中关联一致。
- 12种标志物的蛋白质组特征可用于富集临床试验人群,并避免以既往进展作为入组前提。
研究设计与样本
- 多中心队列分析,发现队列来自加州大学385例,验证队列来自德州大学204例。
- 纳入结缔组织病相关ILD、慢性过敏性肺炎或不可分类ILD患者。
- 使用半定量靶向蛋白质组学平台检测368种血浆生物标志物的相对浓度。
主要发现
- 发现队列中31种生物标志物与进展性纤维化ILD相关,其中17种在验证队列中保持关联。
- 验证的生物标志物与进展性纤维化ILD的关联不受ILD临床诊断影响。
- 机器学习衍生12种生物标志物的蛋白质组特征,在验证队列中敏感度0·90,阴性预测值0·91。
- 低风险蛋白质组特征患者FVC变化为+85·7 mL(95%CI 6·9至164·4),高风险者为-227·1 mL(95%CI -286·7至-167·5)。
- 理论上仅纳入高风险蛋白质组特征患者的临床试验,所需患者数比不考虑该特征的设计减少80%。
关键数值与推荐
- 1年ILD进展定义为死亡、肺移植或FVC相对下降≥10%。
- 蛋白质组特征低风险者中约10%在采血后一年内发生ILD进展。
临床怎么用
- 该蛋白质组特征可用于识别1年内进展风险高的ILD患者,辅助临床监测与试验富集。
- 用于临床试验入组时,可避免要求患者先出现进展,从而减少所需样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Progressive fibrosing interstitial lung disease (ILD) is characterised by parenchymal scar formation, leading to high morbidity and mortality. The ability to predict this phenotype remains elusive. We conducted a proteomic analysis to identify novel plasma biomarkers of progressive fibrosing ILD and developed a proteomic signature to predict this phenotype. METHODS: Relative plasma concentrations for 368 biomarkers were determined with use of a semi-quantitative, targeted proteomic platform in patients with connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, or unclassifiable ILD who provided research blood draws at the University of California (discovery cohort) and the University of Texas (validation cohort). Univariable logistic regression was used to identify individual biomarkers associated with 1-year ILD progression, defined as death, lung transplant, or 10% or greater relative forced vital capacity (FVC) decline. A proteomic signature of progressive fibrosing ILD was then derived with use of machine learning in the University of California cohort and validated in the University of Texas cohort. FINDINGS: The discovery cohort comprised 385 patients (mean age 63·6 years, 59% female) and the validation cohort comprised 204 patients (mean age 60·7 years, 61% female). 31 biomarkers were associated with progressive fibrosing ILD in the discovery cohort, with 17 maintaining an association in the validation cohort. Validated biomarkers showed a consistent association with progressive fibrosing ILD irrespective of ILD clinical diagnosis. A proteomic signature comprising 12 biomarkers was derived by machine learning and validated in the University of Texas cohort, in which it had a sensitivity of 0·90 and corresponding negative predictive value of 0·91, suggesting that approximately 10% of patients with a low-risk proteomic signature would experience ILD progression in the year after blood draw. Those with a low-risk proteomic signature experienced an FVC change of +85·7 mL (95% CI 6·9 to 164·4) and those with a high-risk signature experienced an FVC change of -227·1 mL (-286·7 to -167·5). A theoretical clinical trial restricted to patients with a high-risk proteomic signature would require 80% fewer patients than one designed without regard to proteomic signature. INTERPRETATION: 17 plasma biomarkers of progressive fibrosing ILD were identified and showed consistent associations across ILD subtypes. A proteomic signature of progressive fibrosing ILD could enrich clinical trial cohorts and avoid the need for antecedent progression when defining progressive fibrosing ILD for clinical trial enrolment. FUNDING: National Heart Lung and Blood Institute.
引用
- Bowman WS, Newton CA, Linderholm AL, et al. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respir Med. 2022. PMID: 35063079. doi:10.1016/S2213-2600(21)00503-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。